Vericel Co. (NASDAQ:VCEL) Stock Holdings Increased by Zions Bancorporation N.A.

Zions Bancorporation N.A. boosted its holdings in Vericel Co. (NASDAQ:VCEL - Free Report) by 19.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 38,186 shares of the biotechnology company's stock after purchasing an additional 6,307 shares during the quarter. Zions Bancorporation N.A. owned approximately 0.08% of Vericel worth $2,097,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in VCEL. Advisors Asset Management Inc. boosted its holdings in shares of Vericel by 4.0% in the 3rd quarter. Advisors Asset Management Inc. now owns 16,890 shares of the biotechnology company's stock valued at $714,000 after purchasing an additional 644 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Vericel in the 3rd quarter worth $563,000. Charles Schwab Investment Management Inc. boosted its holdings in Vericel by 1.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 434,206 shares of the biotechnology company's stock valued at $18,345,000 after acquiring an additional 5,504 shares during the last quarter. Cerity Partners LLC grew its position in Vericel by 123.2% during the third quarter. Cerity Partners LLC now owns 67,588 shares of the biotechnology company's stock valued at $2,856,000 after acquiring an additional 37,311 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Vericel during the third quarter valued at about $910,000.

Insider Buying and Selling at Vericel

In other news, insider Jonathan Siegal sold 3,908 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $61.99, for a total value of $242,256.92. Following the completion of the sale, the insider now directly owns 1,206 shares in the company, valued at approximately $74,759.94. The trade was a 76.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the sale, the director now owns 26,595 shares of the company's stock, valued at approximately $1,662,187.50. The trade was a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,092 shares of company stock worth $1,683,582 in the last ninety days. 5.20% of the stock is owned by insiders.

Remove Ads

Analyst Upgrades and Downgrades

VCEL has been the topic of several research analyst reports. Canaccord Genuity Group lifted their price objective on Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Stephens reissued an "overweight" rating and issued a $65.00 target price on shares of Vericel in a research note on Wednesday, January 15th. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. Finally, Truist Financial reissued a "buy" rating and issued a $61.00 price objective (down from $67.00) on shares of Vericel in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, Vericel has a consensus rating of "Moderate Buy" and an average price target of $62.29.

Vericel Stock Down 3.4 %

Shares of Vericel stock traded down $1.57 during trading hours on Friday, hitting $44.50. 298,050 shares of the company's stock traded hands, compared to its average volume of 377,899. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $63.00. The company has a market cap of $2.23 billion, a PE ratio of 741.79 and a beta of 1.78. The stock has a 50 day simple moving average of $53.23 and a 200-day simple moving average of $51.73.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.